Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zai Lab (ZLAB)
NASDAQ:ZLAB
Holding ZLAB?
Track your performance easily
ZLAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.48 - $32.60
Previous Close$18.04
Volume455.82K
Average Volume (3M)591.06K
Market Cap
$1.78B
Enterprise Value$1.19B
Total Cash (Recent Filing)$650.78M
Total Debt (Recent Filing)$63.35M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Aug 06, 2024EPS Estimate
-$0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.50
Shares Outstanding99,208,743
10 Day Avg. Volume456,992
30 Day Avg. Volume591,061
Standard Deviation0.19
R-Squared0.10
Alpha-0.00320
Financial Highlights & Ratios
Price to Book (P/B)2.42
Price to Sales (P/S)6.91
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.10
Enterprise Value/Gross Profit6.99
Enterprise Value/Ebitda-5.56
Forecast
1Y Price Target
$40.67Price Target Upside125.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Zai Lab News
PremiumCompany Announcements
Zai Lab Reports Strong Q3 Growth and Pipeline ProgressBulls Say, Bears Say
Bulls Say
Product PerformanceZai Lab's niraparib achieved monthly sales of RMB76.7mn, capturing 42.4% of the PARP inhibitor market in China.
Regulatory ApprovalThe company’s repotrectinib was approved by NMPA for ROS1-positive NSCLC in China.
RevenueProduct revenues for 1Q24 of $87.1M beat the company-provided consensus estimate of $76M.
Bears Say
CompetitionAnother PARP inhibitor’s NDA review was completed and may get approval, increasing competition in the market.
Dividend PolicyThe company has not declared any dividends per share.
Revenue EstimatesUpdated sales performance and potential increasing competition led to slightly lower revenue estimates for 2024/25/26.
---
Ownership Overview
10.51% Insiders
20.70% Mutual Funds
0.91% Other Institutional Investors
67.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZLAB FAQ
What was Zai Lab’s price range in the past 12 months?
Zai Lab lowest stock price was $13.48 and its highest was $32.60 in the past 12 months.
What is Zai Lab’s market cap?
Currently, no data Available
When is Zai Lab’s upcoming earnings report date?
Zai Lab’s upcoming earnings report date is Aug 06, 2024 which is 115 days ago.
How were Zai Lab’s earnings last quarter?
Zai Lab released its earnings results on May 08, 2024. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.925 by $0.375.
Is Zai Lab overvalued?
According to Wall Street analysts Zai Lab’s price is currently Undervalued.
Does Zai Lab pay dividends?
Zai Lab does not currently pay dividends.
What is Zai Lab’s EPS estimate?
Zai Lab’s EPS estimate is -$0.71.
How many shares outstanding does Zai Lab have?
Zai Lab has 99,608,765 shares outstanding.
What happened to Zai Lab’s price movement after its last earnings report?
Zai Lab reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.925. Following the earnings report the stock price went up 26.795%.
Which hedge fund is a major shareholder of Zai Lab?
Among the largest hedge funds holding Zai Lab’s share is Woodline Partners LP. It holds Zai Lab’s shares valued at 42M.
---
Zai Lab Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.67 (125.94% Upside)
$40.67 (125.94% Upside)
Blogger Sentiment
Bullish
ZLAB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 270.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.54%
12-Months-Change
Fundamentals
Return on Equity
-38.44%
Trailing 12-Months
Asset Growth
-15.52%
Trailing 12-Months
Company Description
Zai Lab
Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.
---
ZLAB Earnings Call
Q1 2024
0:00 / 0:00
---
ZLAB Stock 12 Month Forecast
Average Price Target
$40.67
▲(125.94% Upside)
Technical Analysis
Best Analysts Covering ZLAB
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
+7.17%
reiterated a buy rating 9 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +7.17% per trade.
---